Addition of the immunostimulatory oligonucleotide IMT504 to a seasonal flu vaccine increases hemagglutinin antibody titers in young adult and elder rats, and expands the anti-hemagglutinin antibody repertoire

Nucleic Acid Therapeutics

Volumn 21, Issue 4, 2011, Pages 265-274

  Montaner, Alejandro Daniel ^a,b   Denichilo, Analía ^b   Rodríguez, Juan Manuel ^b   Fló, Juan ^c   López, Ricardo Agustin ^c   Pontoriero, Andrea ^d   Savy, Vilma ^d   Baumeister, Elsa ^d   Frank, Ronald ^e   Zorzopulos, Jorge ^b   Elías, Fernanda ^b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b Fundacion Pablo Cassara   (Argentina)

^c Immunotech SA   (Argentina)

^d Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

^e HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; IMT 504; INFLUENZA VACCINE; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; VIROSOME VACCINE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VIRUS A H1N1; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS PARTICLE; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS; IMMUNE SERA; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; OLIGODEOXYRIBONUCLEOTIDES; RATS; VIRAL PROTEINS;

ANIMALIA; FLU VACCINE; RATTUS;

EID: 80052257020     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2011.0284     Document Type: Article

References (31)

1. B̈EUTLING, U., STADING, K., STRADAL, T., and FRANK, R. (2008). Large-scale analysis of protein-protein interactions using cellulose-bound peptide arrays. Adv. Biochem. Eng. Biotechnol. 110, 115-152.
2. CORTI, D., SUGUITAN, A.L., JR., PINNA, D., SILACCI, C., FERNANDEZ-RODRIGUEZ, B.M., VANZETTA, F., SANTOS, C., LUKE, C.J., TORRES-VELEZ, F.J., TEMPERTON, N.J., WEISS, R.A., SALLUSTO, F., SUBBARAO, K., and LANZA-VECCHIA, A. (2010). Neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663-1673.
3. DAVIS, H.L., WEERATNA, R., WALDSCHMIDT, T.J., TY-GRETT, L., SCHORR, J., KRIEG, A.M., and WEERANTA, R. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160, 870-876. (Pubitemid 28049329)
4. DOLAN, S., NYQUIST, A.C., ONDREJKA, D., TODD, J., GERSHMAN, K., ALEXANDER, J., et al. (2004). Preliminary assessment of the effectiveness of the 2003-2004 inactivated influenza vaccine-Colorado, Denver 2003. Centers for Disease Control and Prevention. Morb. Mortal. Wkly. Rep. 53, 8-11.
5. É́LIAS, F., FLO, J., LOPEZ, R.A., ZORZOPULOS, J., MON-TANER, A., and RODRIGUEZ, J.M. (2003). Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J. Immunol. 171, 3697-3704. (Pubitemid 37254574)
6. ELIAS, F., FLO, J., RODRIGUEZ, J.M., NICHILO, A.D., LOPEZ, R.A., ZORZOPULOS, J., NAGLE, C., LAHOZ, M., and MONTANER, A. (2005). PyNTTTTGT prototype oligonucle-otide IMT504 is a potent adjuvant for the recombinant Hepatitis B vaccine that enhances the Th1 response. Vaccine 23, 3597-3603. (Pubitemid 40602795)
7. ERNST, W.A., KIM, H.J., TUMPEY, T.M., JANSEN, A.D., TAI, W., CRAMER, D.V., ADLER-MOORE, J.P., and FUJII, G. (2006). Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24, 5158-5168. (Pubitemid 43818194)
8. FIORE, A.E., SHAY, D.K., HABER, P., ISKANDER, J.K., UYEKI, T.M., MOOTREY, G., BRESEE, J.S., and COX, N.J. (2007). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rev. 56, 1-54.
9. FRANK, R. (1992). Spot-Synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 48, 9217-9232.
10. GERHARD, W., MOZDZANOWSKA, K., and ZHARIKOVA, D. (2006). Prospects for universal influenza virus vaccine. Emerg. Infect. Dis. 12, 569-574.
11. GHEDIN, E., SENGAMALAY, N.A., SHUMWAY, M., ZA-BORSKY, J., FELDBLYUM, T., SUBBU, V., SPIRO, D.J., SITZ, J., KOO, H., BOLOTOV, P., DERNOVOY, D., TATUSOVA, T., BAO, Y., ST GEORGE, K., TAYLOR, J., LIPMAN, D.J., FRA-SER, C.M., TAUBENBERGER, J.K., and SALZBERG, S.L. (2005). Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 437, 1162-1166. (Pubitemid 41509354)
12. GLEZEN, W.P. (1982). Serious morbidity and mortality associated with influenza epidemics. Epidemiol. Rev. 4, 25-44. (Pubitemid 13249672)
13. GOCNIK, M., FISLOVA, T., SLADKOVA, T., MUCHA, V., KOSTOLANSKY, F., and VARECKOVA, A. (2007). Antibodies specific to the HA2 glycopolypeptide of influenza a virus haemagglutinin with Fusion-Inhibition activity contribute to the protection of mice against lethal infection. J. Gen. Virol. 88, 951-955. (Pubitemid 46359566)
14. GUPTA, K., and COOPER, C. (2008). A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs R. D. 9, 137-145. (Pubitemid 351651997)
15. HALPERIN, S.A., VAN NEST, G., SMITH, B., ABTAHI, S., WHILEY, H., and EIDEN, J.J. (2003). A phase i study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21, 2461-2467. (Pubitemid 36561337)
16. HAMPSON, A.W. (2008). Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann. Acad. Med. Singapore 37, 510-518.
17. HERNANDO-INSUA, A., MONTANER, A.D., RODRIGUEZ, J.M., ELIAS, F., FLO, J., LOPEZ, R.A., ZORZOPULOS, J., HOFER, E.L., and CHASSEING, N.A. (2007). IMT504, the prototype of the immunostimulatory oligonucleotides of the PyNTTTTGT class, increases the number of progenitors of mesenchymal stem cells both in vitro and in vivo: potential use in tissue repair therapy. Stem Cells 25, 1047-1054. (Pubitemid 46572603)
18. ILYINSKII, P.O., THOIDIS, G., and SHNEIDER, A.M. (2008). Development of a vaccine against pandemic influenza viruses: current status and perspectives. Int. Rev. Immunol. 27, 392-426.
19. KHURANA, S., CHEARWAE, W., CASTELLINO, F., MAN-ISCHEWITZ, J., KING, L.R., HONORKIEWICZ, A., ROCK, M.T., EDWARDS, K.M., DEL GIUDICE, G., RAPPUOLI, R., and GOLDING, H. (2010). Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2, 15ra5.
20. KRIEG, A.M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709-760. (Pubitemid 34293438)
21. KUMAR, R., and BURNS, E.A. (2008). Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev. Vaccines 7, 467-479. (Pubitemid 351681640)
22. POLAND, G.A., JACOBSON, R.M., and TARGONSKI, P.V. (2007). Avian and pandemic influenza: an overview. Vaccine 25, 3057-3061. (Pubitemid 46482755)
23. PRABHU, N., PRABAKARAN, M., HO, H.T., VELUMANI, S., QIANG, J., GOUTAMA, M., and KWANG, J. (2009). Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza a virus H5N1 infection. J. Virol. 83, 2553-2562.
24. RODRIGUEZ, J.M., ELIAS, F., FLO, J.M., LOPEZ, R.A., ZORZO-PULOS, J., and MONTANER, A. (2006). Immunostimulatory PyNTTTTGT oligodeoxynucleotides: structural properties and refinement of the active motif. Oligonucleotides 16, 275-285. (Pubitemid 44763321)
25. SMITH, G.J., VIJAYKRISHNA, D., BAHL, J., LYCETT, S.J., WOR-OBEY, M., PYBUS, O.G., MA, S.K., CHEUNG, C.L., RAGHWANI, J.,BHATT, S.,PEIRIS, J.S., GUAN, Y., and RAMBAUT,A. (2009). Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza a epidemic. Nature 59, 1122-1125.
26. STEEL, J., LOWEN, A.C., WANG, T., YONDOLA, M., GAO, Q., H́AYE, K., GARCIA-SASTRE, A., and PALESE, P. (2010). Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 1, 1-9.
27. TOSH, P.K., and POLAND, G.A. (2008). Emerging vaccines for influenza. Expert Opin. Emerg. Drugs 13, 21-40. (Pubitemid 351459413)
28. WEBSTER, R.G., BEAN, W.J., GORMAN, O.T., CHAMBERS, T.M., and KAWAOKA, Y. (1992). Evolution and ecology of influenza a viruses. Microbiol. Rev. 56, 152-179.
29. WILSON, I.A., and COX, N.J. (1990). Structural basis of immune recognition of influenza virus hemagglutinin. Annu. Rev. Immunol. 8, 737-771. (Pubitemid 20135645)
30. WORLD HEALTH ORGANIZATION. (2002). WHO manual on animal influenza diagnosis and surveillance. WHO/CDS/CSR/NCS/2002.5. Available at www.who.int/csr/resources/publications/influenza/en/whocdscsrncs20025rev.pdf (accessed November 24, 2006).
31. ZHAO, G., JIN, H., LI, J., SU, B., DU, X., KANG, Y., WANG, X., and WANG, B. (2009). PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA. Viral Immunol. 22, 131-138.